Fairmount Funds Management LLC

13F Holdings History for Spyre Therapeutics, Inc. - Common Stock, $0.0001 par value (SYRE)

Symbol: SYRE on Nasdaq
Investment type: Equity / Common Stock, $0.0001 par value
Latest Disclosed Ownership: 8.11M shares
Security Ownership: 9.99%

Shares, Excluding Options vs Price

Value, Excluding Options

Peter Evan Harwin ownership in Spyre Therapeutics, Inc. Common Stock, $0.0001 par value (SYRE)

2025-10-17 - Peter Evan Harwin has filed an SCHEDULE 13D/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 8.11M shares of Spyre Therapeutics, Inc. Common Stock, $0.0001 par value (SYRE). This represents 9.99% percent ownership of the company.

Reporting Name	Ownership %	Change	Value $	Shares owned	Change	Activity %	Price	Form	Report date	Filed at
Peter Evan Harwin	9.99%		$136M	8.11M			$16.78	13D/A	10/15/2025	17 Oct 2025 17:00:44

Holdings date	Weight	Change	Value $	Shares	Change	Activity %	Price	All Holders
9/30/2025	6.06%		$67.3M	4.02M			$16.76	Q3 2025
6/30/2025	7.79%		$60.2M	4.02M			$14.97	Q2 2025
3/31/2025	10.1%		$64.8M	4.02M			$16.14	Q1 2025
12/31/2024	9.3%		$93.5M	4.02M			$23.28	Q4 2024
9/30/2024	9.58%		$118M	4.02M			$29.41	Q3 2024
6/30/2024	10.7%	+9.33%	$94.5M	4.02M	+3,639,680	+962%	$23.51	Q2 2024
3/31/2024	1.56%		$14.4M	378K			$37.93	Q1 2024
12/31/2023	0.86%		$8.14M	378K			$21.52	Q4 2023
9/30/2023	0.56%	+0.56%	$4.64M	378K	+378,421	NEW	$12.25	Q3 2023

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.